Literature DB >> 11056051

KLK12 is a novel serine protease and a new member of the human kallikrein gene family-differential expression in breast cancer.

G M Yousef1, A Magklara, E P Diamandis.   

Abstract

Kallikreins are a subgroup of serine proteases that are involved in the posttranslational processing of polypeptide precursors. Growing evidence suggests that many kallikreins are implicated in carcinogenesis. In rodents, kallikreins are encoded by a large multigene family, but in humans, only three genes have been identified. By using the positional candidate approach, we were able to identify a new kallikrein-like gene, tentatively named KLK12 (for kallikrein gene 12). This new gene maps to chromosome 19q13.3-q13.4, is formed of five coding exons, and shows structural similarity to serine proteases and other known kallikreins. KLK12 is expressed in a variety of tissues including salivary gland, stomach, uterus, lung, thymus, prostate, colon, brain, breast, thyroid, and trachea. We identified three splicing forms of KLK12 that are expressed in many tissues. Our preliminary results indicate that the expression of KLK12 is down-regulated at the mRNA level in breast cancer tissues and is up-regulated by steroid hormones in breast and prostate cancer cell lines. This gene may be involved in the pathogenesis and/or progression of certain cancer types and may find applicability as a novel cancer biomarker. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11056051     DOI: 10.1006/geno.2000.6346

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  16 in total

1.  Incorporating inter-relationships between different levels of genomic data into cancer clinical outcome prediction.

Authors:  Dokyoon Kim; Hyunjung Shin; Kyung-Ah Sohn; Anurag Verma; Marylyn D Ritchie; Ju Han Kim
Journal:  Methods       Date:  2014-02-18       Impact factor: 3.608

2.  Serum human kallikrein 7 represents a new marker for cervical cancer.

Authors:  Weiwei Li; Yi Zhao; Lina Ren; Xin Wu
Journal:  Med Oncol       Date:  2014-09-03       Impact factor: 3.064

3.  Clinical significance of human kallikrein 12 gene expression in gastric cancer.

Authors:  En-Hao Zhao; Zhi-Yong Shen; Hua Liu; Xin Jin; Hui Cao
Journal:  World J Gastroenterol       Date:  2012-12-07       Impact factor: 5.742

4.  Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors.

Authors:  Audrey Guillon-Munos; Katerina Oikonomopoulou; Noémie Michel; Chistopher R Smith; Agnès Petit-Courty; Sylvie Canepa; Pascale Reverdiau; Nathalie Heuzé-Vourc'h; Eleftherios P Diamandis; Yves Courty
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

5.  Cleavage activation of human-adapted influenza virus subtypes by kallikrein-related peptidases 5 and 12.

Authors:  Brian S Hamilton; Gary R Whittaker
Journal:  J Biol Chem       Date:  2013-04-23       Impact factor: 5.157

6.  Activation profiles of human kallikrein-related peptidases by proteases of the thrombostasis axis.

Authors:  Hyesook Yoon; Sachiko I Blaber; D Michael Evans; Julie Trim; Maria Aparecida Juliano; Isobel A Scarisbrick; Michael Blaber
Journal:  Protein Sci       Date:  2008-08-12       Impact factor: 6.725

7.  Human kallikrein-related peptidase 12 (KLK12) splice variants expression in breast cancer and their clinical impact.

Authors:  Maroulio Talieri; Marina Devetzi; Andreas Scorilas; Eleana Pappa; Nikolaos Tsapralis; Ioannis Missitzis; Alexandros Ardavanis
Journal:  Tumour Biol       Date:  2012-02-21

8.  The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer.

Authors:  G M Yousef; A Scorilas; A Magklara; N Memari; R Ponzone; P Sismondi; N Biglia; M Abd Ellatif; E P Diamandis
Journal:  Br J Cancer       Date:  2002-11-18       Impact factor: 7.640

9.  Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer.

Authors:  Yi Zhang; Jianfang Liu; Praveen-Kumar Raj-Kumar; Lori A Sturtz; Anupama Praveen-Kumar; Howard H Yang; Maxwell P Lee; J Leigh Fantacone-Campbell; Jeffrey A Hooke; Albert J Kovatich; Craig D Shriver; Hai Hu
Journal:  Breast Cancer Res Treat       Date:  2020-09-02       Impact factor: 4.872

10.  Prior nasal delivery of antagomiR-122 prevents radiation-induced brain injury.

Authors:  Haihong Zhou; Furong Sun; Mingqian Ou; Yu Zhang; Meijun Lin; Liqin Song; Yangsheng Yu; Haojie Liao; Weihao Fan; Huaijie Xing; Minhua Li; Kui Zhao; Xiaolian Wu; Yuanhong Sun; Chunmei Liang; Yujie Cai; Lili Cui
Journal:  Mol Ther       Date:  2021-06-24       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.